ProQR Therapeutics N.V. — 2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020; annual results, not a standalone fourth-quarter report. Financial statements are audited and prepared under IFRS as issued by the IASB, with euro as the presentation and functional currency. ProQR is a clinical-stage RNA therapeutics company with no marketed products and no product-sale or royalty revenue.
Financial performance and liquidity
| Metric (€ millions, except per-share data) | 2020 | 2019 | Change |
|---|---|---|---|
| Other income, primarily grants and credit waiver | 9.452 | 1.933 | +7.519 |
| Research and development expense | 38.135 | 46.491 | -8.356 |
| General and administrative expense | 13.685 | 12.887 | +0.798 |
| Operating loss | 42.368 | 57.445 | Loss narrowed by 15.077 |
| Net loss | 46.614 | 56.746 | Loss narrowed by 10.132 |
| Basic and diluted loss per share | €0.93 | €1.38 | Improved |
| Operating cash used | 47.060 | 43.970 | Use increased by 3.090 |
| Cash and cash equivalents at year-end | 75.838 | 111.950 | -36.112 |
There is no meaningful product gross margin disclosed because the company had no product sales. The operating-loss improvement reflects lower R&D spending and substantially higher other income; it should not be read as evidence of recurring profitability. Other income included an €8.423 million waiver of the innovation credit for the cystic fibrosis program. R&D expense fell partly because COVID-19 delayed clinical trials and because 2019 included Ionis-related payments and more external studies. G&A expense increased modestly.
Cash used in investing activities was €0.924 million; financing generated €14.500 million, mainly from €13.791 million net proceeds from convertible loans. Cash declined by €33.484 million before a negative €2.628 million currency effect. Total assets were €98.729 million, total liabilities €42.183 million, and total equity €56.546 million at year-end. Borrowings were €17.324 million, including €14.247 million of convertible loans and €3.077 million of government borrowing; lease liabilities were €16.953 million. No off-balance-sheet arrangements were reported.
The company stated that existing cash was expected to fund planned operations into 2023, subject to uncertain assumptions. The convertible loan facilities with Pontifax and Kreos had combined capacity of up to $30 million and €15 million; one $10 million tranche and one €5 million tranche had been drawn by year-end. The debt has a 54-month maturity and 24-month interest-only period, with conversion rights and warrants at $7.88 per share. Certain assets, including cash, are pledged as security. The filing does not provide a clear annual revenue or product margin value; it states no product revenue had been generated.
Business, pipeline and changes versus 2019
- Lead candidate sepofarsen was in a Phase 2/3 pivotal trial for LCA10. Enrollment was completed in January 2021; top-line results were expected in the first half of 2022. These dates and expectations are forward-looking statements in the filing.
- QR-421a was in a Phase 1/2 trial for USH2A-related vision loss, and QR-1123 was in a Phase 1/2 trial for P23H autosomal dominant retinitis pigmentosa. The company planned two Phase 2/3 QR-421a trials, subject to regulatory alignment. QR-504a for Fuchs dystrophy was planned to enter an initial clinical trial, subject to COVID-related site restrictions.
- The company also described discovery and preclinical programs, including Axiomer RNA editing and TRIDENT RNA pseudouridylation. Development-stage results do not establish future efficacy or approval.
- Compared with 2019, cash fell from €111.950 million to €75.838 million, liabilities rose from €23.702 million to €42.183 million, and equity declined from €93.833 million to €56.546 million. The 2020 net loss narrowed, but operating cash use increased.
- At December 31, 2020, 54,131,553 ordinary shares were issued; the filing separately reports 50,204,810 outstanding shares for certain calculations. Share options, treasury shares and debt conversion rights could increase dilution. A $75 million ATM program was available, but no shares were sold under it in 2020.
Outlook, risks and unusual items
- Management expected continued operating losses and no product revenue for the foreseeable future, with spending on clinical development, preclinical research and potential commercialization. No numerical earnings or revenue guidance was provided.
- COVID-19 delayed ongoing and scheduled trials, including the sepofarsen pivotal study, and could further affect enrollment, sites, CROs and manufacturing supply. The company said it did not then believe its supply chain had been affected, but cautioned that future disruption was possible.
- Key risks include clinical or regulatory failure, uncertain interpretation of early-stage results, dependence on third-party manufacturers and CROs, intellectual-property and license risks, competition, reimbursement uncertainty, and the need for additional capital. Management’s stated cash runway into 2023 is not assured.
- Potential future payments include up to $37.5 million to Foundation Fighting Blindness following the first commercial sale of QR-421a, and milestone and royalty obligations to Ionis for QR-1123. These are contingent obligations, not current-period expenses necessarily payable immediately.
- Foreign-exchange exposure was material: a 10% weakening of the U.S. dollar against the euro was estimated to increase 2020 net loss by €2.224 million. The company did not hedge currency exposure.
- Management and the auditor concluded that disclosure controls and internal control over financial reporting were effective at December 31, 2020; the auditor issued unqualified opinions on the financial statements and internal controls. Deloitte was to be replaced by KPMG for fiscal 2021, with no reported disagreements or reportable events.
Important facts for investors to verify
- Reconcile the stated cash runway into 2023 with actual cash burn, committed R&D spending, debt service and remaining availability under the convertible facilities.
- Track the pivotal sepofarsen trial’s results and timing, and assess whether clinical evidence supports the filing’s expectations; distinguish later-reported trial updates from information available at year-end 2020.
- Verify the recurring nature of 2020 other income: the €8.423 million innovation-credit waiver was a one-time item, and grant income is not product revenue.
- Review convertible debt terms, pledged assets, conversion and warrant dilution, and the potential use of the ATM facility.
- Assess contingent milestone and royalty exposure under the FFB and Ionis agreements, along with third-party license and manufacturing dependencies.
- Confirm share counts on a consistent basis: issued shares, outstanding shares excluding treasury shares, and potential shares from options, warrants and debt conversion.